
Becton, Dickinson and Company (BDX), a leading global med-tech organization, has made significant strides in cultivating ground-breaking technology, services, and solutions.
Owing to a robust portfolio and superior market positioning, the company looks positioned for stable growth in the about-to-be-reported quarter. However, declining COVID-related revenues will likely have impacted BDX’s Life Sciences segment’s revenues in the fiscal fourth quarter of 2023.